How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.07.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research
Cancer ResearchOncology
2016English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology
Oncology
2016English

Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Annals of Translational Medicine
Medicine
2017English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Case Report of Non-Small Cell Lung Cancer With STRN-ALK Translocation: A Nonresponder to Alectinib

Journal of Nihon University Medical Association
2019English

How Might Treatment of ALK-positive Non-Small Cell Lung Cancer Change in the Near Future?

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy